BR112023002778A2 - Ácido (1r,3s)-3-((5-ciano-4-feniltiazol-2-il) carbamoil) ciclopentano-1-carboxílico e derivados do mesmo para uso no tratamento de doenças das vias aéreas - Google Patents

Ácido (1r,3s)-3-((5-ciano-4-feniltiazol-2-il) carbamoil) ciclopentano-1-carboxílico e derivados do mesmo para uso no tratamento de doenças das vias aéreas

Info

Publication number
BR112023002778A2
BR112023002778A2 BR112023002778A BR112023002778A BR112023002778A2 BR 112023002778 A2 BR112023002778 A2 BR 112023002778A2 BR 112023002778 A BR112023002778 A BR 112023002778A BR 112023002778 A BR112023002778 A BR 112023002778A BR 112023002778 A2 BR112023002778 A2 BR 112023002778A2
Authority
BR
Brazil
Prior art keywords
airway diseases
treatment
phenylthiazol
carbamoyl
cyano
Prior art date
Application number
BR112023002778A
Other languages
English (en)
Portuguese (pt)
Inventor
Castro- Palomino Laria Julio
Camacho Gómez Juan
Castro-Palomino Laria Nahomi
Ariosa Álvarez Alina
Original Assignee
Palobiofarma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palobiofarma Sl filed Critical Palobiofarma Sl
Publication of BR112023002778A2 publication Critical patent/BR112023002778A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
BR112023002778A 2020-08-21 2021-08-20 Ácido (1r,3s)-3-((5-ciano-4-feniltiazol-2-il) carbamoil) ciclopentano-1-carboxílico e derivados do mesmo para uso no tratamento de doenças das vias aéreas BR112023002778A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20382764.7A EP3957308A1 (en) 2020-08-21 2020-08-21 (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases
PCT/EP2021/073133 WO2022038261A1 (en) 2020-08-21 2021-08-20 (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases

Publications (1)

Publication Number Publication Date
BR112023002778A2 true BR112023002778A2 (pt) 2023-03-14

Family

ID=72234795

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002778A BR112023002778A2 (pt) 2020-08-21 2021-08-20 Ácido (1r,3s)-3-((5-ciano-4-feniltiazol-2-il) carbamoil) ciclopentano-1-carboxílico e derivados do mesmo para uso no tratamento de doenças das vias aéreas

Country Status (20)

Country Link
US (1) US20230321053A1 (https=)
EP (2) EP3957308A1 (https=)
JP (1) JP7794807B2 (https=)
KR (1) KR20230054444A (https=)
CN (1) CN115942933A (https=)
AU (1) AU2021327728A1 (https=)
BR (1) BR112023002778A2 (https=)
CA (1) CA3190081A1 (https=)
DK (1) DK4199922T3 (https=)
ES (1) ES3001104T3 (https=)
FI (1) FI4199922T3 (https=)
HR (1) HRP20241621T1 (https=)
HU (1) HUE069338T2 (https=)
LT (1) LT4199922T (https=)
MX (1) MX2023002156A (https=)
PL (1) PL4199922T3 (https=)
PT (1) PT4199922T (https=)
RS (1) RS66263B1 (https=)
SI (1) SI4199922T1 (https=)
WO (1) WO2022038261A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6871948B2 (ja) 2016-04-27 2021-05-19 アッヴィ・インコーポレイテッド 抗il−13抗体を使用する、il−13活性が有害である疾患の治療方法
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070219223A1 (en) * 2006-03-07 2007-09-20 Endacea, Inc. Compositions and methods for treating respiratory disorders
ES2331220B1 (es) * 2007-10-02 2010-09-23 Palobiofarma, S.L. Nuevos compuestos como antagonistas de los receptores a1 de adenosina.
WO2015057668A1 (en) * 2013-10-15 2015-04-23 Medimmune, Llc Methods for treating chronic obstructive pulmonary disease using benralizumab
UA122670C2 (uk) * 2014-09-08 2020-12-28 Сефалон, Інк. Спосіб лікування еозинофільної астми у пацієнта
ES2676535B1 (es) * 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
HRP20211104T1 (hr) * 2017-03-06 2021-10-15 Palobiofarma, S.L. Aminska sol (1r,3s)-3-(5-cijano-4-fenil-1,3-tiazol-2-ilkarbamoil)ciklopentankarboksilne kiseline

Also Published As

Publication number Publication date
WO2022038261A1 (en) 2022-02-24
US20230321053A1 (en) 2023-10-12
JP2023538419A (ja) 2023-09-07
MX2023002156A (es) 2023-03-01
EP4199922B1 (en) 2024-09-25
ES3001104T3 (es) 2025-03-04
JP7794807B2 (ja) 2026-01-06
LT4199922T (lt) 2025-01-10
EP4199922A1 (en) 2023-06-28
PT4199922T (pt) 2024-12-18
DK4199922T3 (da) 2024-11-25
EP3957308A1 (en) 2022-02-23
AU2021327728A1 (en) 2023-03-09
RS66263B1 (sr) 2024-12-31
CN115942933A (zh) 2023-04-07
CA3190081A1 (en) 2022-02-24
HUE069338T2 (hu) 2025-02-28
PL4199922T3 (pl) 2025-02-10
SI4199922T1 (sl) 2025-03-31
FI4199922T3 (fi) 2024-12-05
HRP20241621T1 (hr) 2025-01-31
KR20230054444A (ko) 2023-04-24

Similar Documents

Publication Publication Date Title
Rosenberg et al. Combination of atomoxetine with the novel antimuscarinic aroxybutynin improves mild to moderate OSA
Mandelberg et al. Nebulized 3% hypertonic saline solution treatment in hospitalized infants with viral bronchiolitis
Daviskas et al. Hyperosmolar agents and clearance of mucus in the diseased airway
AU2018357775B2 (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
JP2010511715A5 (https=)
JP2023522010A5 (https=)
WO2013034910A1 (en) Inhalable compositions
JP5492072B2 (ja) 喘息の増悪の予防および/または治療のためのフォルモテロールおよびジプロピオン酸ベクロメタゾンを含む組成物の使用
BR112023002778A2 (pt) Ácido (1r,3s)-3-((5-ciano-4-feniltiazol-2-il) carbamoil) ciclopentano-1-carboxílico e derivados do mesmo para uso no tratamento de doenças das vias aéreas
Teper et al. Inhaled mannitol in patients with cystic fibrosis: a randomised open-label dose response trial
JP2012522767A (ja) ステロイド性[3,2−c]ピラゾール誘導体および第二の薬学的活性化合物を含む医薬組成物
CN108014106A (zh) 卡格列净在制备用于辅助治疗特发性肺纤维化的药物中的应用
Berjis et al. Normal saline versus hypertonic 3% saline: it’s efficacy in non-acute rhinosinusitis
Crescimanno et al. Successful treatment of atelectasis with Dornase alpha in a patient with congenital muscular dystrophy
CN105326789B (zh) 氨溴索沙丁胺醇溶液剂
AU2010322066A1 (en) Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom
Sonkhya et al. Functional Endoscopic sinus surgery in Patients with chronic rhinosinusitis and Polyposis and Asthma
WO2007126001A1 (ja) ロキソプロフェンを含有する鎮咳又は去痰のための医薬組成物
Page et al. Mucolytics/antioxidants: When Are They Useful?
Erkul et al. The effects of septoplasty on QTc dispersion
WO2025250560A1 (en) Methods for treating bronchiectasis
Wang et al. High-frequency oscillation improves mucus clearance and airway resistance in mechanically ventilated patients: a randomized clinical trial
Akıncı Ozyurek et al. Antifibrotic treatment in patients with idiopathic pulmonary fibrosis: Our experience in 41 cases
EP4709379A1 (en) Nmdar antagonist for the treatment of inflammatory diseases in patients with depression comorbidity
CN113694177A (zh) 器官损伤的预防和治疗